NHNobuyuki Hida

Nobuyuki Hida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nobuyuki Hida has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy

    by Keisuke Hata, Soichiro Ishihara, Yoichi Ajioka, Keiichi Mitsuyama, Kenji Watanabe, Hiroyuki Hanai, Reiko Kunisaki, Hiroshi Nakase, Keiji Matsuda, Ryuichi Iwakiri, et al.

    We previously performed a randomized controlled trial (RCT) comparing targeted and random biopsy in neoplasia detection in patients with ulcerative colitis (UC), which showed the short-term effectiveness of targeted biopsy with one-time colonoscopy. In this retrospective cohort study, we investigated the long-term effectiveness of targeted biopsy in tertiary care hospitals, using the follow-up data from patients with UC for ≥ 8 years who had enrolled in the initial RCT. The primary outcome was death from colorectal cancer (CRC). Secondary outcomes were advanced neoplasia (CRC or high-grade dysplasia) and colectomy due to neoplasia after the RCT. We compared these outcomes between target and random groups. Data on 195 of the 221 patients (88.2%) enrolled in the previous RCT were collected from 28 institutions between 2008 and 2019. No patients died of CRC in either group, with a median 8.8-year follow-up demonstrating a robustness for targeted biopsy in terms of CRC death prevention. Advanced neoplasia was detected in four and three patients in the target and random groups, respectively. Colectomy was required due to neoplasia in three patients in each group. The chance of developing CRC in patients with a negative colonoscopy was low, and the targeted biopsy appeared effective in this population. Conversely, patients found with low-grade dysplasia at initial RCT have 10-fold higher risk of progression to high-grade dysplasia and/or CRC. Ten extracolonic malignancies were observed during the follow-up, resulting in four deaths. Panchromoendoscopy was used only in 4.6% and targeted biopsy was only performed in 59.1% of colonoscopies. We recommend targeted biopsy rather than > 33 random biopsies in real-world settings under adequate observation by specialists.


  • Open Access

    Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan

    by Hitoshi Tajiri, Katsuhiro Arai, Seiichi Kagimoto, Reiko Kunisaki, Nobuyuki Hida, Noriko Sato, Hiroshi Yamada, Mieko Nagano, Yutaka Susuta, Kunihiko Ozaki, et al.

    Background: Pediatric ulcerative colitis (UC) is typically more extensive and has a more active disease course than adult UC, and requires early treatment augmentation to achieve and maintain disease remission. The present study aimed to investigate the efficacy, safety, and pharmacokinetic profile of infliximab (IFX) in pediatric patients with moderate-to-severe UC and inadequate response to existing treatment. Methods: This open-label, uncontrolled, multicenter, Phase 3 trial was conducted at 17 centers in Japan between April 2012 and September 2014. Pediatric patients (aged 6–17 years) diagnosed with moderate-to-severe UC received a treatment protocol comprising 5 mg/kg IFX at Weeks 0, 2, and 6, and Clinical Activity Index (CAI)-based responders at Week 8 also received treatment at 8-week intervals at Weeks 14 and 22, with a final evaluation at Week 30. Results: A total of 21 patients were treated in this study. IFX therapy rapidly improved clinical symptoms, and this effect was maintained for up to 30 weeks. Overall CAI-based remission rate was 42.9% and overall Pediatric Ulcerative Colitis Activity Index (PUCAI)-based remission rate was 19.0%. Median partial Mayo score was 6.0 at baseline and 4.0 at Week 30 (overall). Among the eight patients who underwent sigmoidoscopy, Mayo response was achieved at Week 30 (overall) in three patients (37.5%). Trough serum IFX concentrations in Week 8 CAI-based responders were maintained throughout the study period. Adverse events and serious adverse events were observed in 95.2 and 14.3% of patients, respectively. Conclusions: These results support the use of IFX in the treatment of pediatric patients with UC with inadequate response to existing treatment. Trial registration: ClinicalTrials.gov, registration number: NCT01585155.


  • Mo1833 - The Initial Trough Concenrtation at 36 Hours after Starting Tacrolimus is Important for the Personalized Medicine Strategy in Patients with Ulcerative Colitis

    by Nobuyuki Hida, Kenji Watanabe, Takako Miyazaki, Yoko Yokoyama, Tetsuya Takagawa, Koji Kamikozuru, Mikio Kawai, Yuko Kita, Toshiyuki Sato, Shiro Nakamura

  • Mo1893 - Clinical Characteristics and Complications in Hospitalised Elderly Patients with Ulcerative Colitis in a Real-World Specialised Hospital

    by Yuko Kita, Ayako Fujimori, Ryoji Koshiba, Koji Fujimoto, Toshiyuki Sato, Mikio Kawai, Koji Kamikozuru, Tetsuya Takagawa, Yoko Yokoyama, Takako Miyazaki, et al.

  • Mo1912 Long Term Efficacy and Safety of Thiopurines in Patients With Steroid Dependent Ulcerative Colitis: A Retrospective Investigation

    by Yoko Yokoyama, Mikio Kawai, Yuko Kita, Koji Kamikozuru, Takako Miyazaki, Masaki Iimuro, Nobuyuki Hida, Shiro Nakamura

  • Su1849 Pregnancy Outcomes in Patients with Inflammatory Bowel Disease Experiencing Flare ups During Foetal Development

    by Yoko Yokoyama, Takako Miyazaki, Mikio Kawai, Yuko Kita, Koji Kamikozuru, Masaki Iimuro, Nobuyuki Hida, Shiro Nakamura

  • Mo1913 Factors Associated with Re-stenosis and the Need for Surgical Interventions in Patients with Crohn's Disease Undergoing Endoscopic Balloon Dilatation for Lower Gastrointestinal Strictures

    by Koji Kamikozuru, Toshiyuki Sato, Mikio Kawai, Tetsuya Takagawa, Yuko Kita, Yoko Yokoyama, Takako Miyazaki, Masaki Iimuro, Nobuyuki Hida, Shiro Nakamura

    • 1 September 2014
      • Vol. 61  (134) , 1654-60

    Patients' assessment of adalimumab self-injection for Crohn's disease: a multicenter questionnaire survey (The PEARL Survey).

    by Fumihito Hirai, Kenji Watanabe, Takayuki Matsumoto, Masaki Iimuro, Noriko Kamata, Naoya Kubokura, Motohiro Esaki, Hirokazu Yamagami, Yutaka Yano, Nobuyuki Hida, et al.

    Adalimumab (ADA) is a self-injectable anti-tumor necrosis factor-α antibody used for treating Crohn’s disease (CD). Although self-injecting ADA may be convenient for patients, few reports have assessed patients receiving ADA self-injection therapy. We conducted a questionnaire survey involving outpatients on ADA self-injection therapy at four university hospitals. We analyzed the degree of satisfaction with and adherence to the self-injection therapy and performed sub-analyses. Responses were obtained from 124 patients. Before treatment initiation, 38% patients replied that they were unwilling to accept the self-injection therapy. However, after treatment initiation, 75% patients were satisfied with the treatment. 66 patients previously treated with infliximab (IFX), the degree of treatment satisfaction was significantly higher in patients who felt burdened to the time required for IFX infusion than in those who had not felt burdened (P < 0.05). Patient adherence to ADA was high (85%). Multivariate analysis regarding adherence revealed that duration of disease (OR, 0.99), degree of treatment efficacy satisfaction (OR, 13.42), and schedule registration (OR, 7.95) were significant. Safety assessment results were within the range of those already reported. ADA self-injection was thought to have good adherence and a safe administration method according to patients’ assessments.


  • Open Access

    A Questionnaire-Based Survey on the Diagnosis and Management of Inflammatory Bowel Disease in East Asian Countries in 2012

    by Nobuyuki Hida, Shiro Nakamura, Ki-Baik Hahm, Jose D. Sollano, Qi Zhu, Abdul Aziz Rani, Ari Fahrial Syam, Udom Kachintorn, Fumiaki Ueno, Takashi Joh, et al.

    Background and Aim: The prevalence and incidence of inflammatory bowel disease (IBD) are lower in East Asia than in Western countries; however, marked increases have recently been reported. The clinical diagnosis and medical management of IBD in East Asia differ from those in Western countries. A questionnaire-based survey was performed to gather physicians' current opinions on IBD in different East Asian countries. Methods: Representative International Gastrointestinal Consensus Symposium (IGICS) committee members provided a questionnaire to physicians in each East Asian country studied. The questionnaire mainly focused on the diagnosis and management of IBD. Results: There were 19 respondents from Japan, 10 from South Korea, 9 from the Philippines, 6 from China and 4 from Indonesia. Colonoscopy (100%) and histopathology (63%) were commonly used for the diagnosis in ulcerative colitis (UC). Conventional small bowel enteroclysis was still the most common diagnostic tool for assessing small bowel lesions in Crohn's disease (CD) in East Asia. The percentage of physicians who investigated the reactivation of Cytomegalovirus in severe or refractory patients with UC ranged from 0% in the Philippines and Indonesia to 100% in Japan and Korea. Most physicians in Korea, the Philippines, China and Indonesia chose thiopurines or anti-TNF therapy as the second-line treatment in severe refractory UC, whereas Japanese physicians preferred to use tacrolimus or leukocyte apheresis. Physicians in the Philippines and Indonesia preferred to use oral 5-aminosalicylic acid for newly diagnosed severe ileocecal CD. In contrast, Korean physicians chose oral steroids and most physicians in China and Japan preferred to use anti-TNF. Nutritional therapy to induce or maintain remission in patients with CD was commonly used in Indonesia, Japan and China. Targeted biopsies by conventional colonoscopy were the most preferred strategy for cancer surveillance in long-standing UC over random biopsies in this region. Conclusions: The present survey found that current diagnostic approaches and clinical management of IBD vary within East Asian countries.


  • Sa1516 Effectiveness of a New Type Ultrathin Colonoscope in Colonoscopy of Patients With Active Ulcerative Colitis

    by Tomohiro Ogawa, Yoshio Ohda, Tomoaki Kono, Katsuyuki Tozawa, Yoko Yokoyama, Koji Kamikozuru, Nobuyuki Hida, Kazutoshi Hori, Masaki Iimuro, Hiroto Miwa, et al.